概要
Drug safety is a broad topic. Certara’s in silico toxicology software enables pharmaceutical, biotech, chemical, and agrochemical companies to predict toxicological outcomes, assess compound safety, and generate regulatory-ready reports on an easy-to-use interface.
The FDA’s Roadmap to reducing animal testing in preclinical studies (April, 2025) sets out an ambitious and clear objective “to make animal studies the exception rather than the norm for preclinical safety/toxicity testing” within 3-5 years from now.
In this webinar, we introduce ToxStudio®, a suite of in silico tools addressing preclinical safety challenges:
- Libra™ – AI-powered DILI prediction
- Cardiac Safety Simulator™ – Modeling and simulation platform to predict QT/proarrhythmia risk
- Secondary Intelligence™ – Secondary pharmacology software to contextualize and categorize off-target risks
Key Learning Objectives:
- Understand the FDA’s New Approach Methdology (NAMs) Roadmap
- Learn where to start with in silico NAMs for the safety and toxicology assessment
お申込みはこちら
Vice President, Quantitative Systems Toxicology and Safety, Certara
WillはサターラのQSTSチームを統率し、計算科学アプローチを駆使した医薬品やその他の化学物質の安全性評価に取り組んでいます。豊富な実績を誇る安全性薬理学者として、過去にSyntex、Quintiles、AstraZenecaにおいて研究に従事していました。2017年にはSafety Pharmacology SocietyのPresidentを務めました。
お申込みはこちら
